XOMA Royalty Corporation - Common Stock (XOMA)

XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.

For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.

XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.

  During Monday, 102 stocks hit new 52-week lows.

  During Thursday, 56 stocks hit new 52-week lows.

  On Friday, 57 companies reached new 52-week lows.

Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin 

XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%, reporting an EPS of $-0.98 versus an estimate of $-0.5.

Although US stocks closed lower on Friday, there were a few notable insider trades.

  Wednesday saw 59 companies set new 52-week lows.

XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%, reporting an EPS of $-0.98 versus an estimate of $-0.5.

XOMA (NASDAQ:XOMA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:45 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 108.7%, reporting an EPS of $-0.48 versus an estimate of $-0.23.